The epidemiological fitness cost of drug resistance in Mycobacterium tuberculosis.
The emergence of antibiotic resistance in Mycobacterium tuberculosis has raised the concern that pathogen strains that are virtually untreatable may become widespread. The acquisition of resistance to antibiotics results in a longer duration of infection in a host, but this resistance may come at a cost through a decreased transmission rate. This raises the question of whether the overall fitness of drug-resistant strains is higher than that of sensitive strains--essential information for predicting the spread of the disease. Here, we directly estimate the transmission cost of drug resistance, the rate at which resistance evolves, and the relative fitness of resistant strains. These estimates are made by using explicit models of the transmission and evolution of sensitive and resistant strains of M. tuberculosis, using approximate Bayesian computation, and molecular epidemiology data from Cuba, Estonia, and Venezuela. We find that the transmission cost of drug resistance relative to sensitivity can be as low as 10%, that resistance evolves at rates of approximately 0.0025-0.02 per case per year, and that the overall fitness of resistant strains is comparable with that of sensitive strains. Furthermore, the contribution of transmission to the spread of drug resistance is very high compared with acquired resistance due to treatment failure (up to 99%). Estimating such parameters directly from in vivo data will be critical to understanding and responding to antibiotic resistance. For instance, projections using our estimates suggest that the prevalence of tuberculosis may decline with successful treatment, but the proportion of cases associated with resistance is likely to increase.
Luciani
Fabio
F
School of Biotechnology and Biomolecular Sciences, University of New South Wales, Kensington, NSW 2052, Australia.
Sisson
Scott A
SA
Jiang
Honglin
H
Francis
Andrew R
AR
Tanaka
Mark M
MM
D000465:Algorithms; D000995:Antitubercular Agents / Q000627:therapeutic use*; D001499:Bayes Theorem; D003462:Cuba / Q000453:epidemiology; D024901:Drug Resistance, Multiple, Bacterial; D004957:Estonia / Q000453:epidemiology; D006801:Humans; D008962:Models, Theoretical; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy* / Q000453:epidemiology / Q000635:transmission; D014687:Venezuela / Q000453:epidemiology
D000995:Antitubercular Agents
Thorax. 2006 Feb;61(2):158-63
16254056
Nat Med. 2004 Oct;10(10):1111-6
15378053
J Clin Microbiol. 1999 Oct;37(10):3255-9
10488188
Int J Tuberc Lung Dis. 1998 Mar;2(3):187-99
9526190
Genetics. 2006 Jul;173(3):1511-20
16624908
Clin Microbiol Rev. 2006 Oct;19(4):658-85
17041139
Nat Med. 2004 Oct;10(10):1117-21
15378056
Curr Opin Microbiol. 1999 Oct;2(5):489-93
10508723
J Mol Med (Berl). 1998 Aug;76(9):624-36
9725765
J Clin Microbiol. 2001 Sep;39(9):3339-45
11526173
Science. 2006 Sep 15;313(5793):1554
16973846
Eur J Pediatr. 2008 Feb;167(2):141-8
17987316
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8180-5
10859359
Emerg Infect Dis. 2001 Sep-Oct;7(5):842-8
11747697
Proc Biol Sci. 2001 Jan 7;268(1462):45-52
12123297
PLoS Comput Biol. 2006 Oct;2(10):e137
17040124
Antimicrob Agents Chemother. 2002 May;46(5):1204-11
11959546
BMC Microbiol. 2006 Oct 10;6:90
17032442
Science. 2002 Mar 15;295(5562):2042-6
11896268
Proc Natl Acad Sci U S A. 2009 May 5;106(18):7672-7
19365076
Proc Natl Acad Sci U S A. 2006 Oct 10;103(41):15266-71
17015836
J Infect Dis. 2004 Jul 1;190(1):99-106
15195248
Lancet Infect Dis. 2003 Jan;3(1):13-21
12505028
Science. 2006 Jun 30;312(5782):1944-6
16809538
Int J Tuberc Lung Dis. 1998 Sep;2(9):743-50
9755929
Proc Natl Acad Sci U S A. 2007 Feb 6;104(6):1760-5
17264216
Infect Genet Evol. 2008 Mar;8(2):182-90
18243064